Literature DB >> 24620870

Idelalisib--a PI3Kδ inhibitor for B-cell cancers.

David A Fruman1, Lewis C Cantley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24620870      PMCID： PMC4088325          DOI： 10.1056/NEJMe1400055

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Authors:  Richard R Furman; Jeff P Sharman; Steven E Coutre; Bruce D Cheson; John M Pagel; Peter Hillmen; Jacqueline C Barrientos; Andrew D Zelenetz; Thomas J Kipps; Ian Flinn; Paolo Ghia; Herbert Eradat; Thomas Ervin; Nicole Lamanna; Bertrand Coiffier; Andrew R Pettitt; Shuo Ma; Stephan Stilgenbauer; Paula Cramer; Maria Aiello; Dave M Johnson; Langdon L Miller; Daniel Li; Thomas M Jahn; Roger D Dansey; Michael Hallek; Susan M O'Brien
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

2.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors:  Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

Review 3.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

Review 4.  PI3Ks in lymphocyte signaling and development.

Authors:  Klaus Okkenhaug; David A Fruman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 5.  Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.

Authors:  Elisa ten Hacken; Jan A Burger
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

6.  Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha.

Authors:  D A Fruman; S B Snapper; C M Yballe; L Davidson; J Y Yu; F W Alt; L C Cantley
Journal:  Science       Date:  1999-01-15       Impact factor: 47.728

7.  Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase.

Authors:  H Suzuki; Y Terauchi; M Fujiwara; S Aizawa; Y Yazaki; T Kadowaki; S Koyasu
Journal:  Science       Date:  1999-01-15       Impact factor: 47.728

8.  Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.

Authors:  Klaus Okkenhaug; Antonio Bilancio; Géraldine Farjot; Helen Priddle; Sara Sancho; Emma Peskett; Wayne Pearce; Stephen E Meek; Ashreena Salpekar; Michael D Waterfield; Andrew J H Smith; Bart Vanhaesebroeck
Journal:  Science       Date:  2002-07-18       Impact factor: 47.728

Review 9.  What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.

Authors:  Samuel J Klempner; Andrea P Myers; Lewis C Cantley
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

10.  Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K.

Authors:  Mary Ellen Conley; A Kerry Dobbs; Anita M Quintana; Amma Bosompem; Yong-Dong Wang; Elaine Coustan-Smith; Amber M Smith; Elena E Perez; Peter J Murray
Journal:  J Exp Med       Date:  2012-02-20       Impact factor: 14.307
  10 in total
  37 in total

Review 1.  The PI3K Pathway in Human Disease.

Authors:  David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

2.  Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.

Authors:  Karina A Kruth; Mimi Fang; Dawne N Shelton; Ossama Abu-Halawa; Ryan Mahling; Hongxing Yang; Jonathan S Weissman; Mignon L Loh; Markus Müschen; Sarah K Tasian; Michael C Bassik; Martin Kampmann; Miles A Pufall
Journal:  Blood       Date:  2017-04-19       Impact factor: 22.113

3.  Cancer: natural-born killers unleashed.

Authors:  Emilio Hirsch; Francesco Novelli
Journal:  Nature       Date:  2014-06-11       Impact factor: 49.962

4.  Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.

Authors:  Mallory B Shiver; Fade Mahmoud; Ling Gao
Journal:  N Engl J Med       Date:  2015-10-15       Impact factor: 91.245

5.  Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Authors:  Sarah K Tasian; David T Teachey; Yong Li; Feng Shen; Richard C Harvey; I-Ming Chen; Theresa Ryan; Tiffaney L Vincent; Cheryl L Willman; Alexander E Perl; Stephen P Hunger; Mignon L Loh; Martin Carroll; Stephan A Grupp
Journal:  Blood       Date:  2016-10-24       Impact factor: 22.113

6.  Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA.

Authors:  Yuan Huang; Nannan Liu; Jing Liu; Yeying Liu; Chuchu Zhang; Shuaiyu Long; Guang Luo; Lingling Zhang; Yingjie Zhang
Journal:  Cell Cycle       Date:  2019-11-14       Impact factor: 4.534

Review 7.  Understanding phosphoinositides: rare, dynamic, and essential membrane phospholipids.

Authors:  Eamonn J Dickson; Bertil Hille
Journal:  Biochem J       Date:  2019-01-07       Impact factor: 3.857

Review 8.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Authors:  Lauren M Thorpe; Haluk Yuzugullu; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

9.  Phosphoinositide 3-Kinase δ Regulates Dectin-2 Signaling and the Generation of Th2 and Th17 Immunity.

Authors:  Min Jung Lee; Eri Yoshimoto; Shinobu Saijo; Yoichiro Iwakura; Xin Lin; Howard R Katz; Yoshihide Kanaoka; Nora A Barrett
Journal:  J Immunol       Date:  2016-05-18       Impact factor: 5.422

10.  Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.

Authors:  Neeraj Jain; Satishkumar Singh; Georgios Laliotis; Amber Hart; Elizabeth Muhowski; Kristyna Kupcova; Tereza Chrbolkova; Tamer Khashab; Sayan Mullick Chowdhury; Anuvrat Sircar; Fazal Shirazi; Ram Kumar Singh; Lapo Alinari; Jiangjiang Zhu; Ondrej Havranek; Philip Tsichlis; Jennifer Woyach; Robert Baiocchi; Felipe Samaniego; Lalit Sehgal
Journal:  Blood Adv       Date:  2020-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.